Comparative Pharmacology
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus MONOCID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus MONOCID.
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER vs MONOCID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis and death.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g IV every 8 hours for pseudomonal infections; 500 mg to 1 g IV every 8-12 hours for uncomplicated UTIs.
1 g intramuscularly or intravenously every 24 hours; for severe infections, 2 g every 24 hours.
None Documented
None Documented
1.5–2.0 hours in normal renal function; prolonged to 15–30 hours in ESRD.
Terminal elimination half-life: 4-5 hours (prolonged to 12-24 hours in severe renal impairment; dosing adjustment recommended for CrCl <50 mL/min).
Primarily renal (80–90% unchanged via glomerular filtration); biliary/fecal <1%.
Renal: ~90% unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: ~5% (cefonicid undergoes minimal hepatic metabolism; ~4% excreted in feces as parent drug and metabolites).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic